鉴定内微生物驱动的免疫调节和在扩散大B细胞淋巴瘤的治疗影响
Zheng Yijia1, Xiaoyu Li1, Lina Ma1
1School of Pharmacy, Xinjiang Medical University, Urumqi, 830011, China.
Cancer immunology, immunotherapy : CII
|March 3, 2025
概括
内微生物组定义了扩散型大B细胞淋巴瘤 (DLBCL) 的不同亚型,影响患者的生存率和免疫反应. 识别这些与微生物组相关的DLBCL亚型可以指导个性化治疗策略.
科学领域:
- 在瘤学瘤学.
- 微生物组研究 微生物组研究
- 免疫学 免疫学 免疫学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种异质的非霍奇金淋巴瘤.
- 人们越来越认识到内微生物组在DLBCL病原和预后中的作用.
- 了解微生物驱动的瘤特征对于改善患者的治疗结果至关重要.
研究的目的:
- 在DLBCL中识别与微生物组相关的不同亚型.
- 评估这些亚型对患者生存的预后影响.
- 研究微生物组亚型,免疫透和治疗敏感性之间的关系.
主要方法:
- 分析了48名DLBCL患者的转录组和微生物组数据.
- 达成共识的聚类来定义与微生物组相关的亚型.
- 功能丰富,免疫透和单细胞RNA测序分析.
- 药物敏感性预测和细胞系和队列中枢基因的验证.
主要成果:
- 确定了两种与微生物组相关的DLBCL亚型,与整体存活率相关.
- 集群1显示了更高的免疫透率 (Tregs,M0巨细胞) 和抗瘤通路的更好的生存率.
- 集群2呈现较差的结果,富含免疫抑制途径;B细胞异质性和分化动态是关键特征.
结论:
- 内微生物组组成显著影响DLBCL预后和免疫微环境.
- 与微生物组相关的亚型为免疫异质性和B细胞分化提供了洞察力.
- 这些发现支持开发基于微生物组的生物标志物和针对DLBCL的个性化治疗策略.
相关概念视频
02:17The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
01:27Tumor Immunotherapy
461
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
461